These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 24120834)

  • 1. Susceptibility rates in Latin American nations: report from a regional resistance surveillance program (2011).
    Jones RN; Guzman-Blanco M; Gales AC; Gallegos B; Castro AL; Martino MD; Vega S; Zurita J; Cepparulo M; Castanheira M
    Braz J Infect Dis; 2013; 17(6):672-81. PubMed ID: 24120834
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Update of contemporary antimicrobial resistance rates across China: reference testing results for 12 medical centers (2011).
    Jones RN; Castanheira M; Hu B; Ni Y; Lin SS; Mendes RE; Wang Y
    Diagn Microbiol Infect Dis; 2013 Nov; 77(3):258-66. PubMed ID: 24055218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resistance surveillance program report for selected European nations (2011).
    Jones RN; Flonta M; Gurler N; Cepparulo M; Mendes RE; Castanheira M
    Diagn Microbiol Infect Dis; 2014 Apr; 78(4):429-36. PubMed ID: 24440509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antimicrobial susceptibility among Gram-positive and Gram-negative organisms collected from the Latin American region between 2004 and 2015 as part of the Tigecycline Evaluation and Surveillance Trial.
    Vega S; Dowzicky MJ
    Ann Clin Microbiol Antimicrob; 2017 Jul; 16(1):50. PubMed ID: 28701170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antimicrobial susceptibility among gram-positive and gram-negative blood-borne pathogens collected between 2012-2016 as part of the Tigecycline Evaluation and Surveillance Trial.
    Zhang Z; Chen M; Yu Y; Pan S; Liu Y
    Antimicrob Resist Infect Control; 2018; 7():152. PubMed ID: 30564308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tigecycline antimicrobial activity tested against clinical bacteria from Latin American medical centres: results from SENTRY Antimicrobial Surveillance Program (2011-2014).
    Sader HS; Castanheira M; Farrell DJ; Flamm RK; Mendes RE; Jones RN
    Int J Antimicrob Agents; 2016 Aug; 48(2):144-50. PubMed ID: 27291285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The tigecycline evaluation and surveillance trial; assessment of the activity of tigecycline and other selected antibiotics against gram-positive and gram-negative pathogens from France collected between 2004 and 2016.
    Decousser JW; Woerther PL; Soussy CJ; Fines-Guyon M; Dowzicky MJ
    Antimicrob Resist Infect Control; 2018; 7():68. PubMed ID: 29876099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Zyvox Annual Appraisal of Potency and Spectrum program: linezolid surveillance program results for 2008.
    Jones RN; Ross JE; Bell JM; Utsuki U; Fumiaki I; Kobayashi I; Turnidge JD
    Diagn Microbiol Infect Dis; 2009 Dec; 65(4):404-13. PubMed ID: 19913683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ceftaroline activity tested against contemporary Latin American bacterial pathogens (2011).
    Flamm RK; Sader HS; Jones RN
    Braz J Infect Dis; 2014; 18(2):187-95. PubMed ID: 24513484
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity of ceftaroline and comparators against pathogens isolated from skin and soft tissue infections in Latin America - results of AWARE surveillance 2012.
    Hoban D; Biedenbach D; Sahm D; Reiszner E; Iaconis J
    Braz J Infect Dis; 2015; 19(6):596-603. PubMed ID: 26481631
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antimicrobial susceptibility of Gram-negative and Gram-positive bacteria collected from Eastern Europe: Results from the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.), 2011-2016.
    Dowzicky MJ; Chmelařová E
    J Glob Antimicrob Resist; 2019 Jun; 17():44-52. PubMed ID: 30445209
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spectrum and potency of ceftaroline against leading pathogens causing community-acquired respiratory tract and skin and soft tissue infections in Latin America, 2010.
    Flamm RK; Sader HS; Jones RN
    Braz J Infect Dis; 2013; 17(5):564-72. PubMed ID: 23916453
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antimicrobial susceptibility of gram-negative and gram-positive bacteria collected from countries in Eastern Europe: results from the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.) 2004-2010.
    Balode A; Punda-Polić V; Dowzicky MJ
    Int J Antimicrob Agents; 2013 Jun; 41(6):527-35. PubMed ID: 23590898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit.
    Sader HS; Jones RN; Dowzicky MJ; Fritsche TR
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):203-8. PubMed ID: 16105565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activity of tigecycline and comparators against Gram-positive and Gram-negative isolates collected from the Middle East and Africa between 2004 and 2011.
    Kanj SS; Whitelaw A; Dowzicky MJ
    Int J Antimicrob Agents; 2014 Feb; 43(2):170-8. PubMed ID: 24315313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antimicrobial resistance among Gram-negative bacilli isolated from Latin America: results from SENTRY Antimicrobial Surveillance Program (Latin America, 2008-2010).
    Gales AC; Castanheira M; Jones RN; Sader HS
    Diagn Microbiol Infect Dis; 2012 Aug; 73(4):354-60. PubMed ID: 22656912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rates of antimicrobial resistance in Latin America (2004-2007) and in vitro activity of the glycylcycline tigecycline and of other antibiotics.
    Rossi F; García P; Ronzon B; Curcio D; Dowzicky MJ
    Braz J Infect Dis; 2008 Oct; 12(5):405-15. PubMed ID: 19219281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of pathogen occurrences and resistance profiles among infected patients in the intensive care unit: report from the SENTRY Antimicrobial Surveillance Program (North America, 2001).
    Streit JM; Jones RN; Sader HS; Fritsche TR
    Int J Antimicrob Agents; 2004 Aug; 24(2):111-8. PubMed ID: 15288308
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activity of ceftaroline against bacterial isolates causing skin and soft tissue and respiratory tract infections collected in Latin American countries, ATLAS program 2016-2020.
    Mohamed N; Valdez RR; Fandiño C; Baudrit M; Falci DR; Murillo JDC
    J Glob Antimicrob Resist; 2024 Mar; 36():4-12. PubMed ID: 38016592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antimicrobial susceptibility trends among gram-positive and -negative clinical isolates collected between 2005 and 2012 in Mexico: results from the Tigecycline Evaluation and Surveillance Trial.
    Morfin-Otero R; Noriega ER; Dowzicky MJ
    Ann Clin Microbiol Antimicrob; 2015 Dec; 14():53. PubMed ID: 26667651
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.